KT-621 has the potential to provide dupilumab-like activity with an oral small molecule profile for TH2 driven allergic and atopic diseaseKT-621 ...
Amgen has shared (PDF) the first phase 3 data on its $400 million eczema drug, linking the | Amgen has shared the first phase ...
âš¾ MLB power rankings Hiking canyons in City Heights Inside scorched-earth Fletcher fight Things to do this week Seinfeld and Gaffigan in San Diego ...